The company suggests their experimental COVID-19 vaccine, UB-612, has the features and potential to disrupt the traditional vaccine distribution and supply status quo. COVAXX has announced advanced purchase commitments for more than 140 million doses of its UB-612 vaccine for COVID-19. The public and private agreements, totalling over $2.8 million, are to deliver vaccines in […]

Aviptadil, a vasodilator originally developed to treat erectile dysfunction, led to a 72% survival in critically-ill COVID-19 patients. Initial data from an US expanded access  (EA) use of RLF-100™ (aviptadil) in 90 ICU patients with critical COVID-19 and severe comorbidities point to a 72% survival 28 days after initial treatment. According to NeuroRx Inc and […]

While some of the leading players in the race for a COVID-19 vaccine are racing toward the finish line, a range of smaller challengers is still hoping to carve out a market niche in the coming months. One of those, New York’s Covaxx, is rolling out its first swath of supply deals—and touting its shot’s logistics […]